The total score obtained by patients with FA in the Mild Behavioral Impairment Checklist (MBI-C) was significantly higher than that obtained by healthy controls. Neuropsychiatric symptoms, especially ...

Asian-type DEL prevalence among Malay individuals was 25% in donors and 21% in patients, exceeding East Asian averages. Accurate knowledge of blood group variants, including the Asian-type DEL, is ...

Patients who had bone fractures had a 1.5 times higher decline of total body bone mineral density Z-score per year and a worse adiposity profile than those with no fractures. Fragility fractures are ...

Sotatercept at 0.7 mg/kg subcutaneous every 3 weeks optimally balanced efficacy and safety for those with PAH. Sotatercept, a practice-changing therapy for pulmonary arterial hypertension (PAH), ...

Rosalind Kalb is lead senior programs consultant for Can-Do MS, a Colorado-based nonprofit health and wellness organization. Larry Luxner, senior correspondent for Rare Disease Advisor, interviews ...

The mortality rates were 15.5% for the ibrutinib group and 16.3% for the bendamustine group. Significant cardiovascular risks are associated with ibrutinib treatment in patients with chronic ...

This particular combination of mutations and comorbidities led to an aggressive disease course, which was refractory to standard treatments. The report, published in Case Reports in Hematology, ...

For T2 signal intensity (SI), there was a significant and strong correlation between SI and the number of days since the last IUT, with SI initially reduced and recovering over time. A recent study ...

Physical exercise rehabilitation programs can optimize outcomes in patients with PAH, especially when performed under clinical supervision. Continuous patient-facing medical education empowers ...

Sandy Siegel, founder and president of the Siegel Rare Neuroimmune Association (Photo by Larry Luxner) Anthropologist Sandy Siegel launched the group after his late wife was diagnosed with transverse ...

Studies have identified various differences in HDFN management and monitoring practices across the United States that could lead to poorer outcomes. For modern medicine to function at an optimized ...

After an open-label phase 2 trial found proof-of-concept efficacy for nipocalimab in the treatment of pregnant women at high risk of hemolytic disease of the fetus and newborn (HDFN), researchers are ...